{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:08:07Z","timestamp":1793398087124,"version":"4.5.0"},"reference-count":242,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41569-024-01100-3","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T15:47:24Z","timestamp":1731944844000},"page":"315-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Cholesterol crystals in the pathogenesis of atherosclerosis"],"prefix":"10.1038","volume":"22","author":[{"given":"Yvonne","family":"Baumer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0538-9815","authenticated-orcid":false,"given":"Jason","family":"Irei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2574-9176","authenticated-orcid":false,"given":"William A.","family":"Boisvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"1100_CR1","first-page":"1","volume":"47","author":"L Aschoff","year":"1910","unstructured":"Aschoff, L. Zur Morphologie der lipoiden Substanzen. Beitr. Pathol. Anat. Allg. Pathol. 47, 1\u201350 (1910).","journal-title":"Beitr. Pathol. Anat. Allg. Pathol."},{"key":"1100_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/path.1700720110","volume":"72","author":"CI Levene","year":"1956","unstructured":"Levene, C. I. The early lesions of atheroma in the coronary arteries. J. Pathol. Bacteriol. 72, 79\u201382 (1956).","journal-title":"J. Pathol. Bacteriol."},{"key":"1100_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155117","volume":"11","author":"Y Luo","year":"2016","unstructured":"Luo, Y. et al. Modeling of mechanical stress exerted by cholesterol crystallization on atherosclerotic plaques. PLoS ONE 11, e0155117 (2016).","journal-title":"PLoS ONE"},{"key":"1100_CR4","first-page":"49","volume":"48","author":"JH Kiyak","year":"1997","unstructured":"Kiyak, J. H. Cholesterol crystals, smooth muscle cells and new data on the genesis of atherosclerosis. Pol. J. Pathol. 48, 49\u201355 (1997).","journal-title":"Pol. J. Pathol."},{"key":"1100_CR5","doi-asserted-by":"publisher","first-page":"7662","DOI":"10.1073\/pnas.1803119115","volume":"115","author":"N Varsano","year":"2018","unstructured":"Varsano, N. et al. Two polymorphic cholesterol monohydrate crystal structures form in macrophage culture models of atherosclerosis. Proc. Natl Acad. Sci. USA 115, 7662\u20137669 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1100_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.atherosclerosis.2008.06.027","volume":"203","author":"A Vedre","year":"2009","unstructured":"Vedre, A. et al. Physical factors that trigger cholesterol crystallization leading to plaque rupture. Atherosclerosis 203, 89\u201396 (2009).","journal-title":"Atherosclerosis"},{"key":"1100_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1172\/JCI108450","volume":"58","author":"SS Katz","year":"1976","unstructured":"Katz, S. S., Shipley, G. G. & Small, D. M. Physical chemistry of the lipids of human atherosclerotic lesions. Demonstration of a lesion intermediate between fatty streaks and advanced plaques. J. Clin. Invest. 58, 200\u2013211 (1976).","journal-title":"J. Clin. Invest."},{"key":"1100_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0006-3002(63)90580-8","volume":"75","author":"H Bogren","year":"1963","unstructured":"Bogren, H. & Larsson, K. An X-ray-diffraction study of crystalline cholesterol in some pathological deposits in man. Biochim. Biophys. Acta 75, 65\u201369 (1963).","journal-title":"Biochim. Biophys. Acta"},{"key":"1100_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251599","volume":"16","author":"MH Park","year":"2021","unstructured":"Park, M. H. et al. Non-linear optical imaging of atherosclerotic plaques in the context of SIV and HIV infection prominently detects crystalline cholesterol esters. PLoS ONE 16, e0251599 (2021).","journal-title":"PLoS ONE"},{"key":"1100_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202100638","volume":"5","author":"Y Baumer","year":"2021","unstructured":"Baumer, Y., McCurdy, S. G. & Boisvert, W. A. Formation and cellular impact of cholesterol crystals in health and disease. Adv. Biol. 5, e2100638 (2021).","journal-title":"Adv. Biol."},{"key":"1100_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jacl.2010.03.003","volume":"4","author":"GS Abela","year":"2010","unstructured":"Abela, G. S. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. J. Clin. Lipidol. 4, 156\u2013164 (2010).","journal-title":"J. Clin. Lipidol."},{"key":"1100_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01186-z","volume":"8","author":"Y Baumer","year":"2017","unstructured":"Baumer, Y. et al. Hyperlipidemia-induced cholesterol crystal production by endothelial cells promotes atherogenesis. Nat. Commun. 8, 1129 (2017).","journal-title":"Nat. Commun."},{"key":"1100_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4081\/hi.2006.155","volume":"2","author":"C Venturelli","year":"2006","unstructured":"Venturelli, C., Jeannin, G., Sottini, L., Dallera, N. & Scolari, F. Cholesterol crystal embolism (atheroembolism). Heart Int. 2, 155 (2006).","journal-title":"Heart Int."},{"key":"1100_CR14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357\u20131361 (2010).","journal-title":"Nature"},{"key":"1100_CR15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/hep4.1348","volume":"3","author":"GN Ioannou","year":"2019","unstructured":"Ioannou, G. N. et al. Cholesterol crystals in hepatocyte lipid droplets are strongly associated with human nonalcoholic steatohepatitis. Hepatol. Commun. 3, 776\u2013791 (2019).","journal-title":"Hepatol. Commun."},{"key":"1100_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.redox.2017.06.004","volume":"13","author":"S Koka","year":"2017","unstructured":"Koka, S. et al. Endothelial NLRP3 inflammasome activation and arterial neointima formation associated with acid sphingomyelinase during hypercholesterolemia. Redox Biol. 13, 336\u2013344 (2017).","journal-title":"Redox Biol."},{"key":"1100_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011765","volume":"5","author":"K Rajam\u00e4ki","year":"2010","unstructured":"Rajam\u00e4ki, K. et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 5, e11765 (2010).","journal-title":"PLoS ONE"},{"key":"1100_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008596","volume":"7","author":"R Wang","year":"2018","unstructured":"Wang, R. et al. Activation of NLRP3 inflammasome promotes foam cell formation in vascular smooth muscle cells and atherogenesis via HMGB1. J. Am. Heart Assoc. 7, e008596 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"1100_CR19","unstructured":"Jones, G. T. in Diagnosis, Screening and Treatment of Abdominal, Thoracoabdominal and Thoracic Aortic Aneurysms Ch. 3 (ed. Grundmann, R. T.) (IntechOpen, 2011)."},{"key":"1100_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/sca.4950280101","volume":"28","author":"GS Abela","year":"2006","unstructured":"Abela, G. S. & Aziz, K. Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events \u2013 a novel insight into plaque rupture by scanning electron microscopy. Scanning 28, 1\u201310 (2006).","journal-title":"Scanning"},{"issue":"Suppl. 1","key":"1100_CR21","doi-asserted-by":"publisher","first-page":"gfz106.FP072","DOI":"10.1093\/ndt\/gfz106.FP072","volume":"34","author":"E Furukawa","year":"2019","unstructured":"Furukawa, E. et al. The impact of chronic kidney disease on cholesterol crystal embolism in autopsy cases [abstract]. Nephrol. Dial. Transplant. 34 (Suppl. 1), gfz106.FP072 (2019).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1100_CR22","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0272-6386(00)70196-X","volume":"35","author":"M Haas","year":"2000","unstructured":"Haas, M., Spargo, B. H., Wit, E. J. & Meehan, S. M. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am. J. Kidney Dis. 35, 433\u2013447 (2000).","journal-title":"Am. J. Kidney Dis."},{"key":"1100_CR23","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/ijms18061120","volume":"18","author":"X Li","year":"2017","unstructured":"Li, X., Bayliss, G. & Zhuang, S. Cholesterol crystal embolism and chronic kidney disease. Int. J. Mol. Sci. 18, 1120 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"1100_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11901-020-00530-0","volume":"19","author":"H Shroff","year":"2020","unstructured":"Shroff, H. & VanWagner, L. B. Cardiovascular disease in nonalcoholic steatohepatitis: screening and management. Curr. Hepatol. Rep. 19, 315\u2013326 (2020).","journal-title":"Curr. Hepatol. Rep."},{"key":"1100_CR25","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00125-023-05949-w","volume":"66","author":"SS Hammer","year":"2023","unstructured":"Hammer, S. S. et al. Cholesterol crystal formation is a unifying pathogenic mechanism in the development of diabetic retinopathy. Diabetologia 66, 1705\u20131718 (2023).","journal-title":"Diabetologia"},{"key":"1100_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/path.1711140406","volume":"114","author":"KW Walton","year":"1974","unstructured":"Walton, K. W. & Dunkerley, D. J. Studies on the pathogenesis of corneal arcus formation II. Immunofluorescent studies on lipid deposition in the eye of the lipid-fed rabbit. J. Pathol. 114, 217\u2013229 (1974).","journal-title":"J. Pathol."},{"key":"1100_CR27","doi-asserted-by":"publisher","first-page":"564712","DOI":"10.3389\/fimmu.2020.564712","volume":"11","author":"GB Silva","year":"2020","unstructured":"Silva, G. B. et al. Cholesterol crystals and NLRP3 mediated inflammation in the uterine wall decidua in normal and preeclamptic pregnancies. Front. Immunol. 11, 564712 (2020).","journal-title":"Front. Immunol."},{"key":"1100_CR28","unstructured":"Virchow, R. L. K. Cellular Pathology (John Churchill, 1860)."},{"key":"1100_CR29","unstructured":"Marchand, F. Ueber atherosclerosis. Verhandlungen der Kongresse fuer Innere Medizin Vol. 21 (1904)."},{"key":"1100_CR30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1161\/CIRCRESAHA.116.310527","volume":"120","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. How common is residual inflammatory risk? Circ. Res. 120, 617\u2013619 (2017).","journal-title":"Circ. Res."},{"key":"1100_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fcvm.2019.00016","volume":"6","author":"AW Aday","year":"2019","unstructured":"Aday, A. W. & Ridker, P. M. Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease. Front. Cardiovasc. Med. 6, 16 (2019).","journal-title":"Front. Cardiovasc. Med."},{"key":"1100_CR32","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","volume":"61","author":"SM Nidorf","year":"2013","unstructured":"Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A. & Thompson, P. L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 61, 404\u2013410 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1100_CR34","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif, J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497\u20132505 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR35","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf, S. M. et al. Colchicine in patients with chronic coronary disease. N. Engl. J. Med. 383, 1838\u20131847 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR36","doi-asserted-by":"publisher","first-page":"102876","DOI":"10.1016\/j.ebiom.2020.102876","volume":"59","author":"Y Baumer","year":"2020","unstructured":"Baumer, Y. et al. Hyperlipidaemia and IFN\u03b3\/TNF\u03b1 synergism are associated with cholesterol crystal formation in endothelial cells partly through modulation of lysosomal pH and cholesterol homeostasis. eBioMedicine 59, 102876 (2020).","journal-title":"eBioMedicine"},{"key":"1100_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.97179","volume":"3","author":"Y Baumer","year":"2018","unstructured":"Baumer, Y. et al. Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis. JCI Insight 3, e97179 (2018).","journal-title":"JCI Insight"},{"key":"1100_CR38","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/path.4873","volume":"241","author":"B Ho-Tin-No\u00e9","year":"2017","unstructured":"Ho-Tin-No\u00e9, B. et al. Cholesterol crystallization in human atherosclerosis is triggered in smooth muscle cells during the transition from fatty streak to fibroatheroma. J. Pathol. 241, 671\u2013682 (2017).","journal-title":"J. Pathol."},{"key":"1100_CR39","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/ni.2639","volume":"14","author":"FJ Sheedy","year":"2013","unstructured":"Sheedy, F. J. et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol. 14, 812\u2013820 (2013).","journal-title":"Nat. Immunol."},{"key":"1100_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0022-2275(20)40131-2","volume":"35","author":"RK Tangirala","year":"1994","unstructured":"Tangirala, R. K. et al. Formation of cholesterol monohydrate crystals in macrophage-derived foam cells. J. Lipid Res. 35, 93\u2013104 (1994).","journal-title":"J. Lipid Res."},{"key":"1100_CR41","doi-asserted-by":"crossref","unstructured":"Capua-Shenkar, J., Varsano, N., Kruth, H. S. & Addadi, L. in Cholesterol Crystals in Atherosclerosis and Other Related Diseases (eds Abela, G. S. & Nidorf, S. M.) 49\u201371 (Humana, 2023).","DOI":"10.1007\/978-3-031-41192-2_4"},{"key":"1100_CR42","doi-asserted-by":"crossref","unstructured":"Nidorf, S. M. & Abela, G. S. in Cholesterol Crystals in Atherosclerosis and Other Related Diseases (eds Abela, G. S. & Nidorf, S. M.) 15\u201326 (Humana, 2023).","DOI":"10.1007\/978-3-031-41192-2_2"},{"key":"1100_CR43","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1172\/JCI115935","volume":"90","author":"FM Konikoff","year":"1992","unstructured":"Konikoff, F. M., Chung, D. S., Donovan, J. M., Small, D. M. & Carey, M. C. Filamentous, helical, and tubular microstructures during cholesterol crystallization from bile. Evidence that cholesterol does not nucleate classic monohydrate plates. J. Clin. Invest. 90, 1155\u20131160 (1992).","journal-title":"J. Clin. Invest."},{"key":"1100_CR44","doi-asserted-by":"publisher","first-page":"9656","DOI":"10.1073\/pnas.0702967104","volume":"104","author":"B Khaykovich","year":"2007","unstructured":"Khaykovich, B. et al. Structure of cholesterol helical ribbons and self-assembling biological springs. Proc. Natl Acad. Sci. USA 104, 9656\u20139660 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1100_CR45","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0368-1319(65)80024-2","volume":"5","author":"JA Wilkens","year":"1965","unstructured":"Wilkens, J. A. & Krut, L. H. The effect of glucose on the crystallization of cholesterol. J. Atheroscler. Res. 5, 516\u2013523 (1965).","journal-title":"J. Atheroscler. Res."},{"key":"1100_CR46","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.bbamem.2009.04.004","volume":"1788","author":"Y Self-Medlin","year":"2009","unstructured":"Self-Medlin, Y., Byun, J., Jacob, R. F., Mizuno, Y. & Mason, R. P. Glucose promotes membrane cholesterol crystalline domain formation by lipid peroxidation. Biochim. Biophys. Acta 1788, 1398\u20131403 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"1100_CR47","doi-asserted-by":"publisher","first-page":"21872","DOI":"10.1021\/jacs.0c10674","volume":"142","author":"S Park","year":"2020","unstructured":"Park, S., Sut, T. N., Ma, G. J., Parikh, A. N. & Cho, N. J. Crystallization of cholesterol in phospholipid membranes follows Ostwald\u2019s rule of stages. J. Am. Chem. Soc. 142, 21872\u201321882 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"1100_CR48","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1021\/ja511642t","volume":"137","author":"N Varsano","year":"2015","unstructured":"Varsano, N., Fargion, I., Wolf, S. G., Leiserowitz, L. & Addadi, L. Formation of 3D cholesterol crystals from 2D nucleation sites in lipid bilayer membranes: implications for atherosclerosis. J. Am. Chem. Soc. 137, 1601\u20131607 (2015).","journal-title":"J. Am. Chem. Soc."},{"key":"1100_CR49","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3233\/CH-2012-1530","volume":"51","author":"D Tziakas","year":"2012","unstructured":"Tziakas, D. et al. Red blood cell distribution width: a strong prognostic marker in cardiovascular disease: is associated with cholesterol content of erythrocyte membrane. Clin. Hemorheol. Microcirc. 51, 243\u2013254 (2012).","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"1100_CR50","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.jacc.2006.08.069","volume":"49","author":"DN Tziakas","year":"2007","unstructured":"Tziakas, D. N. et al. Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability? J. Am. Coll. Cardiol. 49, 2081\u20132089 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1100_CR51","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1126\/science.aan4183","volume":"359","author":"L Cantuti-Castelvetri","year":"2018","unstructured":"Cantuti-Castelvetri, L. et al. Defective cholesterol clearance limits remyelination in the aged central nervous system. Science 359, 684\u2013688 (2018).","journal-title":"Science"},{"key":"1100_CR52","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1089\/ars.2023.0498","volume":"41","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Endothelial cell-derived cholesterol crystals promote endothelial inflammation in early atherogenesis. Antioxid. Redox Signal. 41, 201\u2013215 (2024).","journal-title":"Antioxid. Redox Signal."},{"key":"1100_CR53","doi-asserted-by":"publisher","first-page":"66s","DOI":"10.1083\/jcb.91.3.66s","volume":"91","author":"DF Bainton","year":"1981","unstructured":"Bainton, D. F. The discovery of lysosomes. J. Cell Biol. 91, 66s\u201376s (1981).","journal-title":"J. Cell Biol."},{"key":"1100_CR54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205475119","volume":"119","author":"J Capua-Shenkar","year":"2022","unstructured":"Capua-Shenkar, J. et al. Examining atherosclerotic lesions in three dimensions at the nanometer scale with cryo-FIB-SEM. Proc. Natl Acad. Sci. USA 119, e2205475119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1100_CR55","first-page":"160","volume":"41","author":"H Shio","year":"1979","unstructured":"Shio, H., Haley, N. J. & Fowler, S. Characterization of lipid-laden aortic cells from cholesterol-fed rabbits. III. Intracellular localization of cholesterol and cholesteryl ester. Lab. Invest. 41, 160\u2013167 (1979).","journal-title":"Lab. Invest."},{"key":"1100_CR56","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.tcb.2017.07.006","volume":"27","author":"AM Thelen","year":"2017","unstructured":"Thelen, A. M. & Zoncu, R. Emerging roles for the lysosome in lipid metabolism. Trends Cell Biol. 27, 833\u2013850 (2017).","journal-title":"Trends Cell Biol."},{"key":"1100_CR57","doi-asserted-by":"publisher","first-page":"18521","DOI":"10.1073\/pnas.2010682117","volume":"117","author":"MN Trinh","year":"2020","unstructured":"Trinh, M. N. et al. Last step in the path of LDL cholesterol from lysosome to plasma membrane to ER is governed by phosphatidylserine. Proc. Natl Acad. Sci. USA 117, 18521\u201318529 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1100_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11425-0","volume":"10","author":"S Heybrock","year":"2019","unstructured":"Heybrock, S. et al. Lysosomal integral membrane protein-2 (LIMP-2\/SCARB2) is involved in lysosomal cholesterol export. Nat. Commun. 10, 3521 (2019).","journal-title":"Nat. Commun."},{"key":"1100_CR59","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2015.02.019","volume":"161","author":"BB Chu","year":"2015","unstructured":"Chu, B. B. et al. Cholesterol transport through lysosome-peroxisome membrane contacts. Cell 161, 291\u2013306 (2015).","journal-title":"Cell"},{"key":"1100_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12152-2","volume":"10","author":"D H\u00f6glinger","year":"2019","unstructured":"H\u00f6glinger, D. et al. NPC1 regulates ER contacts with endocytic organelles to mediate cholesterol egress. Nat. Commun. 10, 4276 (2019).","journal-title":"Nat. Commun."},{"key":"1100_CR61","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","volume":"4","author":"FM Platt","year":"2018","unstructured":"Platt, F. M., d\u2019Azzo, A., Davidson, B. L., Neufeld, E. F. & Tifft, C. J. Lysosomal storage diseases. Nat. Rev. Dis. Prim. 4, 27 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1100_CR62","first-page":"99","volume":"35","author":"A Tylki-Szyma\u0144ska","year":"2014","unstructured":"Tylki-Szyma\u0144ska, A. & Jurecka, A. Lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease. Pril 35, 99\u2013106 (2014).","journal-title":"Pril"},{"key":"1100_CR63","unstructured":"Wilson, D. P. et al. Lysosomal Acid Lipase Deficiency (MDText.com, 2000)."},{"key":"1100_CR64","first-page":"100833","volume":"30","author":"F Baronio","year":"2022","unstructured":"Baronio, F. et al. Diagnosis, treatment, and follow-up of a case of Wolman disease with hemophagocytic lymphohistiocytosis. Mol. Genet. Metab. Rep. 30, 100833 (2022).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"1100_CR65","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1194\/jlr.M600390-JLR200","volume":"48","author":"BE Cox","year":"2007","unstructured":"Cox, B. E., Griffin, E. E., Ullery, J. C. & W. Gray, J. Effects of cellular cholesterol loading on macrophage foam cell lysosome acidifications. J. Lipid Res. 48, 1012\u20131021 (2007).","journal-title":"J. Lipid Res."},{"key":"1100_CR66","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1017\/S1431927608080069","volume":"14","author":"WG Jerome","year":"2008","unstructured":"Jerome, W. G., Cox, B. E., Griffin, E. E. & Ullery, J. C. Lysosomal cholesterol accumulation inhibits subsequent hydrolysis of lipoprotein cholesteryl ester. Microsc. Microanal. 14, 138\u2013149 (2008).","journal-title":"Microsc. Microanal."},{"key":"1100_CR67","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2217\/17460875.2.3.357","volume":"2","author":"AB Munkacsi","year":"2007","unstructured":"Munkacsi, A. B., Porto, A. F. & Sturley, S. L. Niemann\u2013Pick type C disease proteins: orphan transporters or membrane rheostats? Fut. Lipidol. 2, 357\u2013367 (2007).","journal-title":"Fut. Lipidol."},{"key":"1100_CR68","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2015.10.002","volume":"64","author":"M Acu\u00f1a","year":"2016","unstructured":"Acu\u00f1a, M. et al. Transgenic overexpression of Niemann\u2013Pick C2 protein promotes cholesterol gallstone formation in mice. J. Hepatol. 64, 361\u2013369 (2016).","journal-title":"J. Hepatol."},{"key":"1100_CR69","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.3390\/ijms22052532","volume":"22","author":"MJC van der Lienden","year":"2021","unstructured":"van der Lienden, M. J. C. et al. GCase and LIMP2 abnormalities in the liver of Niemann Pick type C mice. Int. J. Mol. Sci. 22, 2532 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1100_CR70","doi-asserted-by":"publisher","first-page":"790568","DOI":"10.3389\/fcell.2021.790568","volume":"9","author":"F Cabrera-Reyes","year":"2021","unstructured":"Cabrera-Reyes, F., Parra-Ruiz, C., Yuseff, M. I. & Zanlungo, S. Alterations in lysosome homeostasis in lipid-related disorders: impact on metabolic tissues and immune cells. Front. Cell Dev. Biol. 9, 790568 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1100_CR71","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ymeth.2014.12.014","volume":"75","author":"J Hasegawa","year":"2015","unstructured":"Hasegawa, J., Maejima, I., Iwamoto, R. & Yoshimori, T. Selective autophagy: lysophagy. Methods 75, 128\u2013132 (2015).","journal-title":"Methods"},{"key":"1100_CR72","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jmb.2019.08.010","volume":"432","author":"C Papadopoulos","year":"2020","unstructured":"Papadopoulos, C., Kravic, B. & Meyer, H. Repair or lysophagy: dealing with damaged lysosomes. J. Mol. Biol. 432, 231\u2013239 (2020).","journal-title":"J. Mol. Biol."},{"key":"1100_CR73","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.devcel.2019.10.025","volume":"52","author":"J Jia","year":"2020","unstructured":"Jia, J. et al. Galectin-3 coordinates a cellular system for lysosomal repair and removal. Dev. Cell 52, 69\u201387.e8 (2020).","journal-title":"Dev. Cell"},{"key":"1100_CR74","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s10020-024-00809-8","volume":"30","author":"J Thazhathveettil","year":"2024","unstructured":"Thazhathveettil, J., Kumawat, A. K., Demirel, I., Sirsj\u00f6, A. & Paramel, G. V. Vascular smooth muscle cells in response to cholesterol crystals modulates inflammatory cytokines release and promotes neutrophil extracellular trap formation. Mol. Med. 30, 42 (2024).","journal-title":"Mol. Med."},{"key":"1100_CR75","doi-asserted-by":"publisher","unstructured":"Baumer, Y. et al. Social determinants modulate NK cell activity via obesity, LDL, and DUSP1 signaling. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.09.12.556825 (2023).","DOI":"10.1101\/2023.09.12.556825"},{"key":"1100_CR76","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1476-5381.2012.02110.x","volume":"168","author":"BL Heckmann","year":"2013","unstructured":"Heckmann, B. L., Yang, X., Zhang, X. & Liu, J. The autophagic inhibitor 3-methyladenine potently stimulates PKA-dependent lipolysis in adipocytes. Br. J. Pharmacol. 168, 163\u2013171 (2013).","journal-title":"Br. J. Pharmacol."},{"key":"1100_CR77","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1093\/eurheartj\/ehaa505","volume":"41","author":"Y Baumer","year":"2020","unstructured":"Baumer, Y., Mehta, N. N., Dey, A. K., Powell-Wiley, T. M. & Boisvert, W. A. Cholesterol crystals and atherosclerosis. Eur. Heart J. 41, 2236\u20132239 (2020).","journal-title":"Eur. Heart J."},{"key":"1100_CR78","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13075-015-0645-y","volume":"17","author":"LM Mullen","year":"2015","unstructured":"Mullen, L. M., Chamberlain, G. & Sacre, S. Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease. Arthritis Res. Ther. 17, 122 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"1100_CR79","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/eji.201041316","volume":"41","author":"S Freigang","year":"2011","unstructured":"Freigang, S. et al. Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur. J. Immunol. 41, 2040\u20132051 (2011).","journal-title":"Eur. J. Immunol."},{"key":"1100_CR80","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1161\/ATVBAHA.117.309575","volume":"37","author":"T van der Heijden","year":"2017","unstructured":"van der Heijden, T. et al. NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-deficient mice \u2013 brief report. Arterioscler. Thromb. Vasc. Biol. 37, 1457\u20131461 (2017).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1100_CR81","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.2279","volume":"17","author":"B Vandanmagsar","year":"2011","unstructured":"Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179\u2013188 (2011).","journal-title":"Nat. Med."},{"key":"1100_CR82","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.3390\/jcm12186022","volume":"12","author":"IM Ni\u021bulescu","year":"2023","unstructured":"Ni\u021bulescu, I. M., Ciulei, G., Cozma, A., Procopciuc, L. M. & Or\u0103\u0219an, O. H. From innate immunity to metabolic disorder: a review of the NLRP3 inflammasome in diabetes mellitus. J. Clin. Med. 12, 6022 (2023).","journal-title":"J. Clin. Med."},{"key":"1100_CR83","doi-asserted-by":"publisher","first-page":"454","DOI":"10.5551\/jat.RV17048","volume":"28","author":"J Shi","year":"2021","unstructured":"Shi, J., Guo, J., Li, Z., Xu, B. & Miyata, M. Importance of NLRP3 inflammasome in abdominal aortic aneurysms. J. Atheroscler. Thromb. 28, 454\u2013466 (2021).","journal-title":"J. Atheroscler. Thromb."},{"key":"1100_CR84","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","volume":"15","author":"S Toldo","year":"2018","unstructured":"Toldo, S. & Abbate, A. The NLRP3 inflammasome in acute myocardial infarction. Nat. Rev. Cardiol. 15, 203\u2013214 (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"1100_CR85","doi-asserted-by":"publisher","first-page":"879021","DOI":"10.3389\/fnagi.2022.879021","volume":"14","author":"HM Blevins","year":"2022","unstructured":"Blevins, H. M., Xu, Y., Biby, S. & Zhang, S. The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front. Aging Neurosci. 14, 879021 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"1100_CR86","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","volume":"122","author":"A Grebe","year":"2018","unstructured":"Grebe, A., Hoss, F. & Latz, E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ. Res. 122, 1722\u20131740 (2018).","journal-title":"Circ. Res."},{"key":"1100_CR87","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3390\/cells9071642","volume":"9","author":"MW Socha","year":"2020","unstructured":"Socha, M. W., Malinowski, B., Puk, O., Dubiel, M. & Wici\u0144ski, M. The NLRP3 inflammasome role in the pathogenesis of pregnancy induced hypertension and preeclampsia. Cells 9, 1642 (2020).","journal-title":"Cells"},{"key":"1100_CR88","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1194\/jlr.M072454","volume":"58","author":"GN Ioannou","year":"2017","unstructured":"Ioannou, G. N. et al. Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH. J. Lipid Res. 58, 1067\u20131079 (2017).","journal-title":"J. Lipid Res."},{"key":"1100_CR89","first-page":"100317","volume":"35","author":"GS Abela","year":"2023","unstructured":"Abela, G. S. et al. Cholesterol crystals induce mechanical trauma, inflammation, and neo-vascularization in solid cancers as in atherosclerosis. Am. Heart J. 35, 100317 (2023).","journal-title":"Am. Heart J."},{"key":"1100_CR90","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jjcc.2024.03.003","volume":"84","author":"M Khair","year":"2024","unstructured":"Khair, M., Khair, M., Vangaveti, V. N. & Malabu, U. H. The role of the NLRP3 inflammasome in atherosclerotic disease: systematic review and meta-analysis. J. Cardiol. 84, 14\u201321 (2024).","journal-title":"J. Cardiol."},{"key":"1100_CR91","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.gendis.2023.01.009","volume":"11","author":"X Que","year":"2024","unstructured":"Que, X., Zheng, S., Song, Q., Pei, H. & Zhang, P. Fantastic voyage: the journey of NLRP3 inflammasome activation. Genes. Dis. 11, 819\u2013829 (2024).","journal-title":"Genes. Dis."},{"key":"1100_CR92","doi-asserted-by":"publisher","first-page":"eabe2933","DOI":"10.1126\/sciimmunol.abe2933","volume":"6","author":"G-M Ren","year":"2021","unstructured":"Ren, G.-M. et al. Pharmacological targeting of NLRP3 deubiquitination for treatment of NLRP3-associated inflammatory diseases. Sci. Immunol. 6, eabe2933 (2021).","journal-title":"Sci. Immunol."},{"key":"1100_CR93","doi-asserted-by":"publisher","first-page":"100534","DOI":"10.1016\/j.jlr.2024.100534","volume":"65","author":"M Yalcinkaya","year":"2024","unstructured":"Yalcinkaya, M. et al. Cholesterol trafficking to the ER leads to activation of CaMKII\/JNK\/NLRP3 and promotes atherosclerosis. J. Lipid Res. 65, 100534 (2024).","journal-title":"J. Lipid Res."},{"key":"1100_CR94","doi-asserted-by":"publisher","first-page":"eabf2489","DOI":"10.1126\/sciimmunol.abf2489","volume":"6","author":"N Niyonzima","year":"2021","unstructured":"Niyonzima, N. et al. Mitochondrial C5aR1 activity in macrophages controls IL-1\u03b2 production underlying sterile inflammation. Sci. Immunol. 6, eabf2489 (2021).","journal-title":"Sci. Immunol."},{"key":"1100_CR95","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41581-023-00704-1","volume":"19","author":"EE West","year":"2023","unstructured":"West, E. E. & Kemper, C. Complosome \u2013 the intracellular complement system. Nat. Rev. Nephrol. 19, 426\u2013439 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"1100_CR96","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.4049\/jimmunol.1302484","volume":"192","author":"EO Samstad","year":"2014","unstructured":"Samstad, E. O. et al. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J. Immunol. 192, 2837\u20132845 (2014).","journal-title":"J. Immunol."},{"key":"1100_CR97","doi-asserted-by":"publisher","first-page":"25322","DOI":"10.1074\/jbc.M115.645234","volume":"290","author":"R Kiyotake","year":"2015","unstructured":"Kiyotake, R. et al. Human Mincle binds to cholesterol crystals and triggers innate immune responses. J. Biol. Chem. 290, 25322\u201325332 (2015).","journal-title":"J. Biol. Chem."},{"key":"1100_CR98","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41420-023-01444-8","volume":"9","author":"R-Z Tan","year":"2023","unstructured":"Tan, R.-Z. et al. Macrophages mediate psoriasis via Mincle-dependent mechanism in mice. Cell Death Discov. 9, 140 (2023).","journal-title":"Cell Death Discov."},{"key":"1100_CR99","doi-asserted-by":"publisher","first-page":"111744","DOI":"10.1016\/j.yexcr.2019.111744","volume":"387","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. SIRT6 inhibits cholesterol crystal-induced vascular endothelial dysfunction via Nrf2 activation. Exp. Cell Res. 387, 111744 (2020).","journal-title":"Exp. Cell Res."},{"key":"1100_CR100","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.freeradbiomed.2018.05.068","volume":"123","author":"AM Mani","year":"2018","unstructured":"Mani, A. M., Chattopadhyay, R., Singh, N. K. & Rao, G. N. Cholesterol crystals increase vascular permeability by inactivating SHP2 and disrupting adherens junctions. Free. Radic. Biol. Med. 123, 72\u201384 (2018).","journal-title":"Free. Radic. Biol. Med."},{"key":"1100_CR101","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0021-9150(89)90085-3","volume":"77","author":"WJ McConathy","year":"1989","unstructured":"McConathy, W. J., Koren, E. & Stiers, D. L. Cholesterol crystal uptake and metabolism by P388D1 macrophages. Atherosclerosis 77, 221\u2013225 (1989).","journal-title":"Atherosclerosis"},{"key":"1100_CR102","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1126\/science.aaa8064","volume":"349","author":"A Warnatsch","year":"2015","unstructured":"Warnatsch, A., Ioannou, M., Wang, Q. & Papayannopoulos, V. Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science 349, 316\u2013320 (2015).","journal-title":"Science"},{"key":"1100_CR103","doi-asserted-by":"publisher","first-page":"112526","DOI":"10.1016\/j.yexcr.2021.112526","volume":"402","author":"Z Zheng","year":"2021","unstructured":"Zheng, Z. et al. Protective effect of SIRT6 on cholesterol crystal-induced endothelial dysfunction via regulating ACE2 expression. Exp. Cell Res. 402, 112526 (2021).","journal-title":"Exp. Cell Res."},{"key":"1100_CR104","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.imbio.2014.06.006","volume":"219","author":"S Nymo","year":"2014","unstructured":"Nymo, S., Niyonzima, N., Espevik, T. & Mollnes, T. E. Cholesterol crystal-induced endothelial cell activation is complement-dependent and mediated by TNF. Immunobiology 219, 786\u2013792 (2014).","journal-title":"Immunobiology"},{"key":"1100_CR105","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/CIRCRESAHA.115.306361","volume":"118","author":"MR Bennett","year":"2016","unstructured":"Bennett, M. R., Sinha, S. & Owens, G. K. Vascular smooth muscle cells in atherosclerosis. Circ. Res. 118, 692\u2013702 (2016).","journal-title":"Circ. Res."},{"key":"1100_CR106","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1093\/cvr\/cvab046","volume":"117","author":"MOJ Grootaert","year":"2021","unstructured":"Grootaert, M. O. J. & Bennett, M. R. Vascular smooth muscle cells in atherosclerosis: time for a re-assessment. Cardiovasc. Res. 117, 2326\u20132339 (2021).","journal-title":"Cardiovasc. Res."},{"key":"1100_CR107","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1161\/CIRCRESAHA.120.315931","volume":"126","author":"Y D\u00f6ring","year":"2020","unstructured":"D\u00f6ring, Y., Libby, P. & Soehnlein, O. Neutrophil extracellular traps participate in cardiovascular diseases. Circ. Res. 126, 1228\u20131241 (2020).","journal-title":"Circ. Res."},{"key":"1100_CR108","doi-asserted-by":"publisher","first-page":"787541","DOI":"10.3389\/fphar.2021.787541","volume":"12","author":"SR Botts","year":"2021","unstructured":"Botts, S. R., Fish, J. E. & Howe, K. L. Dysfunctional vascular endothelium as a driver of atherosclerosis: emerging insights into pathogenesis and treatment. Front. Pharmacol. 12, 787541 (2021).","journal-title":"Front. Pharmacol."},{"key":"1100_CR109","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1089\/ars.2014.5978","volume":"22","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y. et al. Coronary endothelial dysfunction induced by nucleotide oligomerization domain-like receptor protein with pyrin domain containing 3 inflammasome activation during hypercholesterolemia: beyond inflammation. Antioxid. Redox Signal. 22, 1084\u20131096 (2015).","journal-title":"Antioxid. Redox Signal."},{"key":"1100_CR110","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/cvr\/cvac189","volume":"119","author":"M Yalcinkaya","year":"2023","unstructured":"Yalcinkaya, M. et al. Cholesterol accumulation in macrophages drives NETosis in atherosclerotic plaques via IL-1\u03b2 secretion. Cardiovasc. Res. 119, 969\u2013981 (2023).","journal-title":"Cardiovasc. Res."},{"key":"1100_CR111","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1136\/ard.2009.122655","volume":"69","author":"A Waldiceu","year":"2010","unstructured":"Waldiceu, A. et al. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann. Rheum. Dis. 69, 1697\u20131703 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1100_CR112","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.atherosclerosis.2019.05.029","volume":"287","author":"Y Baumer","year":"2019","unstructured":"Baumer, Y. et al. Ultramorphological analysis of plaque advancement and cholesterol crystal formation in Ldlr knockout mouse atherosclerosis. Atherosclerosis 287, 100\u2013111 (2019).","journal-title":"Atherosclerosis"},{"key":"1100_CR113","first-page":"705","volume":"134","author":"JR Guyton","year":"1989","unstructured":"Guyton, J. R. & Klemp, K. F. The lipid-rich core region of human atherosclerotic fibrous plaques. Prevalence of small lipid droplets and vesicles by electron microscopy. Am. J. Pathol. 134, 705\u2013717 (1989).","journal-title":"Am. J. Pathol."},{"key":"1100_CR114","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1161\/01.ATV.14.8.1305","volume":"14","author":"JR Guyton","year":"1994","unstructured":"Guyton, J. R. & Klemp, K. F. Development of the atherosclerotic core region. Chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta. Arterioscler. Thromb. 14, 1305\u20131314 (1994).","journal-title":"Arterioscler. Thromb."},{"key":"1100_CR115","first-page":"19","volume":"36","author":"F Parker","year":"1960","unstructured":"Parker, F. An electron microscopic study of experimental atherosclerosis. Am. J. Pathol. 36, 19\u201353 (1960).","journal-title":"Am. J. Pathol."},{"key":"1100_CR116","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2016.03.007","volume":"248","author":"PA Cahill","year":"2016","unstructured":"Cahill, P. A. & Redmond, E. M. Vascular endothelium \u2013 gatekeeper of vessel health. Atherosclerosis 248, 97\u2013109 (2016).","journal-title":"Atherosclerosis"},{"key":"1100_CR117","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.carpath.2012.06.006","volume":"22","author":"MA Gimbrone Jr.","year":"2013","unstructured":"Gimbrone, M. A. Jr. & Garcia-Cardena, G. Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Cardiovasc. Pathol. 22, 9\u201315 (2013).","journal-title":"Cardiovasc. Pathol."},{"key":"1100_CR118","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","volume":"118","author":"MA Gimbrone Jr.","year":"2016","unstructured":"Gimbrone, M. A. Jr. & Garcia-Cardena, G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ. Res. 118, 620\u2013636 (2016).","journal-title":"Circ. Res."},{"key":"1100_CR119","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Boren","year":"2020","unstructured":"Boren, J. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 41, 2313\u20132330 (2020).","journal-title":"Eur. Heart J."},{"key":"1100_CR120","first-page":"1444","volume":"143","author":"JR Guyton","year":"1993","unstructured":"Guyton, J. R. & Klemp, K. F. Transitional features in human atherosclerosis. Intimal thickening, cholesterol clefts, and cell loss in human aortic fatty streaks. Am. J. Pathol. 143, 1444\u20131457 (1993).","journal-title":"Am. J. Pathol."},{"key":"1100_CR121","first-page":"191","volume":"103","author":"RG Gerrity","year":"1981","unstructured":"Gerrity, R. G. The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions. Am. J. Pathol. 103, 191\u2013200 (1981).","journal-title":"Am. J. Pathol."},{"key":"1100_CR122","doi-asserted-by":"publisher","first-page":"D429","DOI":"10.2741\/Kruth","volume":"6","author":"HS Kruth","year":"2001","unstructured":"Kruth, H. S. Macrophage foam cells and atherosclerosis. Front. Biosci. 6, D429\u2013D455 (2001).","journal-title":"Front. Biosci."},{"key":"1100_CR123","doi-asserted-by":"crossref","unstructured":"Baumer, Y., Ortiz-Whittingham, L. R., Baez, A. S., Powell-Wiley, T. M. & Boisvert, W. A. in Cholesterol Crystals in Atherosclerosis and Other Related Diseases (eds Abela, G. S. & Nidorf, S. M.) 127\u2013142 (Humana, 2023).","DOI":"10.1007\/978-3-031-41192-2_8"},{"key":"1100_CR124","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross, R. Atherosclerosis \u2013 an inflammatory disease. N. Engl. J. Med. 340, 115\u2013126 (1999).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR125","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand, J. M. et al. Risk of myocardial infarction in patients with psoriasis. JAMA 296, 1735\u20131741 (2006).","journal-title":"JAMA"},{"key":"1100_CR126","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41392-022-01125-5","volume":"7","author":"Y Duan","year":"2022","unstructured":"Duan, Y. et al. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal. Transduct. Target. Ther. 7, 265 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1100_CR127","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/11914","volume":"22","author":"M Bodzioch","year":"1999","unstructured":"Bodzioch, M. et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22, 347\u2013351 (1999).","journal-title":"Nat. Genet."},{"key":"1100_CR128","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/11905","volume":"22","author":"A Brooks-Wilson","year":"1999","unstructured":"Brooks-Wilson, A. et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22, 336\u2013345 (1999).","journal-title":"Nat. Genet."},{"key":"1100_CR129","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/11921","volume":"22","author":"S Rust","year":"1999","unstructured":"Rust, S. et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22, 352\u2013355 (1999).","journal-title":"Nat. Genet."},{"key":"1100_CR130","doi-asserted-by":"crossref","unstructured":"Goodman, Z., Terracciano, L. & Wee, A. in MacSween\u2019s Pathology of the Liver 6th edn Ch. 14 (eds Burt, A. D., Portmann, B. C. & Ferrell, L. D.) 761\u2013851 (Churchill Livingstone, 2011).","DOI":"10.1016\/B978-0-7020-3398-8.00014-3"},{"key":"1100_CR131","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10654-022-00956-4","volume":"38","author":"M Amiri","year":"2023","unstructured":"Amiri, M. et al. Circulating lipoprotein(a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis. Eur. J. Epidemiol. 38, 485\u2013499 (2023).","journal-title":"Eur. J. Epidemiol."},{"key":"1100_CR132","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/00365513.2010.550311","volume":"71","author":"PR Kamstrup","year":"2011","unstructured":"Kamstrup, P. R., Tybjaerg-Hansen, A. & Nordestgaard, B. G. Lipoprotein(a) and risk of myocardial infarction \u2013 genetic epidemiologic evidence of causality. Scand. J. Clin. Lab. Invest. 71, 87\u201393 (2011).","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"1100_CR133","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1056\/NEJM199005243222104","volume":"322","author":"M Seed","year":"1990","unstructured":"Seed, M. et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N. Engl. J. Med. 322, 1494\u20131499 (1990).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR134","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/archinte.168.6.598","volume":"168","author":"A Bennet","year":"2008","unstructured":"Bennet, A. et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch. Intern. Med. 168, 598\u2013608 (2008).","journal-title":"Arch. Intern. Med."},{"key":"1100_CR135","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","volume":"361","author":"R Clarke","year":"2009","unstructured":"Clarke, R. et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518\u20132528 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR136","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"The Emerging Risk Factors Collaboration","year":"2009","unstructured":"The Emerging Risk Factors Collaboration Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302, 412\u2013423 (2009).","journal-title":"JAMA"},{"key":"1100_CR137","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","volume":"5","author":"D Saleheen","year":"2017","unstructured":"Saleheen, D. et al. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. Lancet Diabetes Endocrinol. 5, 524\u2013533 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1100_CR138","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jacc.2021.10.044","volume":"79","author":"Y Kaiser","year":"2022","unstructured":"Kaiser, Y. et al. Association of lipoprotein(a) with atherosclerotic plaque progression. J. Am. Coll. Cardiol. 79, 223\u2013233 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1100_CR139","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MOL.0000000000000681","volume":"31","author":"A Langsted","year":"2020","unstructured":"Langsted, A. & Nordestgaard, B. G. Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality? Curr. Opin. Lipidol. 31, 125\u2013131 (2020).","journal-title":"Curr. Opin. Lipidol."},{"key":"1100_CR140","doi-asserted-by":"publisher","first-page":"905363","DOI":"10.3389\/fcvm.2022.905363","volume":"9","author":"C Xue","year":"2022","unstructured":"Xue, C. et al. The relationships between cholesterol crystals, NLRP3 inflammasome, and coronary atherosclerotic plaque vulnerability in acute coronary syndrome: an optical coherence tomography study. Front. Cardiovasc. Med. 9, 905363 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"1100_CR141","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.amjcard.2008.12.019","volume":"103","author":"GS Abela","year":"2009","unstructured":"Abela, G. S. et al. Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes. Am. J. Cardiol. 103, 959\u2013968 (2009).","journal-title":"Am. J. Cardiol."},{"key":"1100_CR142","doi-asserted-by":"publisher","first-page":"11493","DOI":"10.1002\/chem.201802251","volume":"24","author":"MB Al-Handawi","year":"2018","unstructured":"Al-Handawi, M. B. et al. Mechanical and crystallographic analysis of cholesterol crystals puncturing biological membranes. Chemistry 24, 11493\u201311497 (2018).","journal-title":"Chemistry"},{"key":"1100_CR143","first-page":"406","volume":"22","author":"RJ Frink","year":"2010","unstructured":"Frink, R. J. Parallel cholesterol crystals: a sign of impending plaque rupture? J. Invasive Cardiol. 22, 406\u2013411 (2010).","journal-title":"J. Invasive Cardiol."},{"key":"1100_CR144","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jacl.2020.07.003","volume":"14","author":"SM Nidorf","year":"2020","unstructured":"Nidorf, S. M., Fiolet, A. & Abela, G. S. Viewing atherosclerosis through a crystal lens: how the evolving structure of cholesterol crystals in atherosclerotic plaque alters its stability. J. Clin. Lipidol. 14, 619\u2013630 (2020).","journal-title":"J. Clin. Lipidol."},{"key":"1100_CR145","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2020-001274","volume":"7","author":"LA El-Khatib","year":"2020","unstructured":"El-Khatib, L. A. et al. Cholesterol induced heart valve inflammation and injury: efficacy of cholesterol lowering treatment. Open. Heart 7, e001274 (2020).","journal-title":"Open. Heart"},{"issue":"Suppl. 2","key":"1100_CR146","first-page":"3719","volume":"41","author":"ST Niepmann","year":"2020","unstructured":"Niepmann, S. T. et al. Dissolving cholesterol crystals reduces aortic valve stenosis development in mice [abstract ehaa946]. Eur. Heart J. 41 (Suppl. 2), 3719 (2020).","journal-title":"Eur. Heart J."},{"key":"1100_CR147","first-page":"53","volume":"13","author":"M Boumegouas","year":"2021","unstructured":"Boumegouas, M. et al. Cholesterol crystal induced inflammation and mechanical cardiac valve injury: implications for transcatheter aortic-valve replacement. Interv. Cardiol. 13, 53\u201357 (2021).","journal-title":"Interv. Cardiol."},{"key":"1100_CR148","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031997","volume":"13","author":"B Al\u2010Kassou","year":"2024","unstructured":"Al\u2010Kassou, B. et al. Cholesterol crystal dissolution rate of serum predicts outcomes in patients with aortic stenosis undergoing transcatheter aortic valve replacement. J. Am. Heart Assoc. 13, e031997 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1100_CR149","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.3390\/cells12222647","volume":"12","author":"MG Filipovic","year":"2023","unstructured":"Filipovic, M. G. & Luedi, M. M. Cardiovascular biomarkers: current status and future directions. Cells 12, 2647 (2023).","journal-title":"Cells"},{"key":"1100_CR150","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030764","volume":"12","author":"A Rempakos","year":"2023","unstructured":"Rempakos, A., Prescott, B., Mitchell, G. F., Vasan, R. S. & Xanthakis, V. Association of life\u2019s essential 8 with cardiovascular disease and mortality: the Framingham Heart Study. J. Am. Heart Assoc. 12, e030764 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"1100_CR151","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/1457496917738923","volume":"107","author":"J Lieberg","year":"2018","unstructured":"Lieberg, J. et al. Mortality after elective and ruptured abdominal aortic aneurysm surgical repair: 12-year single-center experience of Estonia. Scand. J. Surg. 107, 152\u2013157 (2018).","journal-title":"Scand. J. Surg."},{"key":"1100_CR152","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/sj.ki.5000263","volume":"69","author":"A Meyrier","year":"2006","unstructured":"Meyrier, A. Cholesterol crystal embolism: diagnosis and treatment. Kidney Int. 69, 1308\u20131312 (2006).","journal-title":"Kidney Int."},{"key":"1100_CR153","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202301316R","volume":"37","author":"C Shi","year":"2023","unstructured":"Shi, C., Mammadova-Bach, E., Li, C., Liu, D. & Anders, H.-J. Pathophysiology and targeted treatment of cholesterol crystal embolism and the related thrombotic angiopathy. FASEB J. 37, e23179 (2023).","journal-title":"FASEB J."},{"key":"1100_CR154","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMicm1815615","volume":"381","author":"H Lazareth","year":"2019","unstructured":"Lazareth, H. & Karras, A. Cholesterol crystal embolization after transcatheter aortic-valve replacement. N. Engl. J. Med. 381, 655 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR155","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell, P. B. et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 42, e168\u2013e185 (2022).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1100_CR156","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1194\/jlr.M034876","volume":"54","author":"GN Ioannou","year":"2013","unstructured":"Ioannou, G. N., Haigh, W. G., Thorning, D. & Savard, C. Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. J. Lipid Res. 54, 1326\u20131334 (2013).","journal-title":"J. Lipid Res."},{"key":"1100_CR157","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.116.003497","volume":"10","author":"P Wu","year":"2017","unstructured":"Wu, P. et al. Preeclampsia and future cardiovascular health. Circ. Cardiovasc. Qual. Outcomes 10, e003497 (2017).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"1100_CR158","doi-asserted-by":"publisher","first-page":"a023473","DOI":"10.1101\/cshperspect.a023473","volume":"5","author":"T Hod","year":"2015","unstructured":"Hod, T., Cerdeira, A. S. & Karumanchi, S. A. Molecular mechanisms of preeclampsia. Cold Spring Harb. Perspect. Med. 5, a023473 (2015).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1100_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2022.05.062","volume":"16","author":"C Salafia","year":"2022","unstructured":"Salafia, C. et al. Pregnancy-induced hypertension: the potential role of cholesterol crystals in the maternal decidua. J. Clin. Lipidol. 16, e75 (2022).","journal-title":"J. Clin. Lipidol."},{"key":"1100_CR160","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jsps.2023.04.002","volume":"31","author":"A Matyori","year":"2023","unstructured":"Matyori, A., Brown, C. P., Ali, A. & Sherbeny, F. Statins utilization trends and expenditures in the U.S. before and after the implementation of the 2013 ACC\/AHA guidelines. Saudi Pharm. J. 31, 795\u2013800 (2023).","journal-title":"Saudi Pharm. J."},{"key":"1100_CR161","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1194\/jlr.M053785","volume":"56","author":"GN Ioannou","year":"2015","unstructured":"Ioannou, G. N. et al. Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH. J. Lipid Res. 56, 277\u2013285 (2015).","journal-title":"J. Lipid Res."},{"key":"1100_CR162","doi-asserted-by":"publisher","first-page":"7818","DOI":"10.3390\/ijms24097818","volume":"24","author":"JA Inia","year":"2023","unstructured":"Inia, J. A. et al. Atorvastatin attenuates diet-induced non-alcoholic steatohepatitis in APOE*3-Leiden mice by reducing hepatic inflammation. Int. J. Mol. Sci. 24, 7818 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1100_CR163","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/1074248418776261","volume":"23","author":"AJ Boland","year":"2018","unstructured":"Boland, A. J. et al. Simvastatin suppresses interleukin I\u03b2 release in human peripheral blood mononuclear cells stimulated with cholesterol crystals. J. Cardiovasc. Pharmacol. Ther. 23, 509\u2013517 (2018).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"1100_CR164","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.amjcard.2011.02.336","volume":"107","author":"GS Abela","year":"2011","unstructured":"Abela, G. S. et al. Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. Am. J. Cardiol. 107, 1710\u20131717 (2011).","journal-title":"Am. J. Cardiol."},{"key":"1100_CR165","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"AV Khera","year":"2011","unstructured":"Khera, A. V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127\u2013135 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR166","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jphs.2021.11.005","volume":"148","author":"M Matsuo","year":"2022","unstructured":"Matsuo, M. ABCA1 and ABCG1 as potential therapeutic targets for the prevention of atherosclerosis. J. Pharmacol. Sci. 148, 197\u2013203 (2022).","journal-title":"J. Pharmacol. Sci."},{"key":"1100_CR167","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1056\/NEJMe2403036","volume":"390","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne, C. M. & Nambi, V. HDL therapeutics \u2013 time for a curtain call or time to reconceptualize? N. Engl. J. Med. 390, 1622\u20131623 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR168","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4049\/jimmunol.1403044","volume":"195","author":"N Niyonzima","year":"2015","unstructured":"Niyonzima, N. et al. Reconstituted high-density lipoprotein attenuates cholesterol crystal-induced inflammatory responses by reducing complement activation. J. Immunol. 195, 257\u2013264 (2015).","journal-title":"J. Immunol."},{"key":"1100_CR169","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/imm.12638","volume":"149","author":"SG Thacker","year":"2016","unstructured":"Thacker, S. G. et al. High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation. Immunology 149, 306\u2013319 (2016).","journal-title":"Immunology"},{"key":"1100_CR170","doi-asserted-by":"publisher","first-page":"103725","DOI":"10.1016\/j.ebiom.2021.103725","volume":"74","author":"Y Luo","year":"2021","unstructured":"Luo, Y. et al. Phospholipid nanoparticles: therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. eBioMedicine 74, 103725 (2021).","journal-title":"eBioMedicine"},{"key":"1100_CR171","first-page":"619","volume":"75","author":"L Zhang","year":"2020","unstructured":"Zhang, L. Cyclodextrin related drug delivery system to promote atherosclerosis regression. Pharmazie 75, 619\u2013625 (2020).","journal-title":"Pharmazie"},{"key":"1100_CR172","doi-asserted-by":"publisher","first-page":"107620","DOI":"10.1016\/j.pharmthera.2020.107620","volume":"214","author":"M Mahjoubin-Tehran","year":"2020","unstructured":"Mahjoubin-Tehran, M., Kovanen, P. T., Xu, S., Jamialahmadi, T. & Sahebkar, A. Cyclodextrins: potential therapeutics against atherosclerosis. Pharmacol. Ther. 214, 107620 (2020).","journal-title":"Pharmacol. Ther."},{"key":"1100_CR173","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.atherosclerosis.2019.01.034","volume":"283","author":"K Pilely","year":"2019","unstructured":"Pilely, K. et al. Alpha-cyclodextrin inhibits cholesterol crystal-induced complement-mediated inflammation: a potential new compound for treatment of atherosclerosis. Atherosclerosis 283, 35\u201342 (2019).","journal-title":"Atherosclerosis"},{"key":"1100_CR174","doi-asserted-by":"publisher","first-page":"333ra350","DOI":"10.1126\/scitranslmed.aad6100","volume":"8","author":"S Zimmer","year":"2016","unstructured":"Zimmer, S. et al. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci. Transl. Med. 8, 333ra350 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1100_CR175","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.4049\/jimmunol.1700302","volume":"199","author":"SS Bakke","year":"2017","unstructured":"Bakke, S. S. et al. Cyclodextrin reduces cholesterol crystal-induced inflammation by modulating complement activation. J. Immunol. 199, 2910\u20132920 (2017).","journal-title":"J. Immunol."},{"key":"1100_CR176","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/1440-1681.12285","volume":"41","author":"AM Lopez","year":"2014","unstructured":"Lopez, A. M. et al. Systemic administration of 2-hydroxypropyl-\u03b2-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function. Clin. Exp. Pharmacol. Physiol. 41, 780\u2013787 (2014).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"1100_CR177","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.metabol.2008.02.020","volume":"57","author":"EM Wagner","year":"2008","unstructured":"Wagner, E. M., Jen, K. L., Artiss, J. D. & Remaley, A. T. Dietary alpha-cyclodextrin lowers low-density lipoprotein cholesterol and alters plasma fatty acid profile in low-density lipoprotein receptor knockout mice on a high-fat diet. Metabolism 57, 1046\u20131051 (2008).","journal-title":"Metabolism"},{"key":"1100_CR178","doi-asserted-by":"publisher","unstructured":"Sakurai, T. et al. Dietary \u03b1-cyclodextrin reduces atherosclerosis and modifies gut flora in apolipoprotein E-deficient mice. Mol. Nutr. Food Res. 61, https:\/\/doi.org\/10.1002\/mnfr.201600804 (2017).","DOI":"10.1002\/mnfr.201600804"},{"key":"1100_CR179","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/foods11081118","volume":"11","author":"T Zhu","year":"2022","unstructured":"Zhu, T. et al. Beneficial effects of three dietary cyclodextrins on preventing fat accumulation and remodeling gut microbiota in mice fed a high-fat diet. Foods 11, 1118 (2022).","journal-title":"Foods"},{"key":"1100_CR180","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12944-016-0284-6","volume":"15","author":"MJA Amar","year":"2016","unstructured":"Amar, M. J. A. et al. Randomized double blind clinical trial on the effect of oral \u03b1-cyclodextrin on serum lipids. Lipids Health Dis. 15, 115 (2016).","journal-title":"Lipids Health Dis."},{"key":"1100_CR181","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4103\/0975-7406.67003","volume":"2","author":"G Tiwari","year":"2010","unstructured":"Tiwari, G., Tiwari, R. & Rai, A. K. Cyclodextrins in delivery systems: applications. J. Pharm. Bioallied Sci. 2, 72\u201379 (2010).","journal-title":"J. Pharm. Bioallied Sci."},{"key":"1100_CR182","doi-asserted-by":"publisher","first-page":"716357","DOI":"10.3389\/fimmu.2021.716357","volume":"12","author":"T Houben","year":"2021","unstructured":"Houben, T. et al. Pro-inflammatory implications of 2-hydroxypropyl-\u03b2-cyclodextrin treatment. Front. Immunol. 12, 716357 (2021).","journal-title":"Front. Immunol."},{"key":"1100_CR183","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12951-023-02040-9","volume":"21","author":"L Zhu","year":"2023","unstructured":"Zhu, L. et al. Biomimetic nanoparticles to enhance the reverse cholesterol transport for selectively inhibiting development into foam cell in atherosclerosis. J. Nanobiotechnol 21, 307 (2023).","journal-title":"J. Nanobiotechnol"},{"key":"1100_CR184","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220681","volume":"220","author":"M Itoh","year":"2023","unstructured":"Itoh, M. et al. Lysosomal cholesterol overload in macrophages promotes liver fibrosis in a mouse model of NASH. J. Exp. Med. 220, e20220681 (2023).","journal-title":"J. Exp. Med."},{"key":"1100_CR185","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050262","volume":"7","author":"H Appelqvist","year":"2012","unstructured":"Appelqvist, H. et al. Sensitivity to lysosome-dependent cell death is directly regulated by lysosomal cholesterol content. PLoS ONE 7, e50262 (2012).","journal-title":"PLoS ONE"},{"key":"1100_CR186","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41392-021-00778-y","volume":"6","author":"M Cao","year":"2021","unstructured":"Cao, M., Luo, X., Wu, K. & He, X. Targeting lysosomes in human disease: from basic research to clinical applications. Signal. Transduct. Target. Ther. 6, 379 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1100_CR187","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3389\/fonc.2020.01156","volume":"10","author":"F Geisslinger","year":"2020","unstructured":"Geisslinger, F., M\u00fcller, M., Vollmar, A. M. & Bartel, K. Targeting lysosomes in cancer as promising strategy to overcome chemoresistance \u2013 a mini review. Front. Oncol. 10, 1156 (2020).","journal-title":"Front. Oncol."},{"key":"1100_CR188","doi-asserted-by":"publisher","first-page":"658995","DOI":"10.3389\/fcell.2021.658995","volume":"9","author":"ARA Marques","year":"2021","unstructured":"Marques, A. R. A., Ramos, C., Machado-Oliveira, G. & Vieira, O. V. Lysosome (dys)function in atherosclerosis\u2013 a big weight on the shoulders of a small organelle. Front. Cell Dev. Biol. 9, 658995 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1100_CR189","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cmet.2012.02.011","volume":"15","author":"B Razani","year":"2012","unstructured":"Razani, B. et al. Autophagy links inflammasomes to atherosclerotic progression. Cell Metab. 15, 534\u2013544 (2012).","journal-title":"Cell Metab."},{"key":"1100_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15750","volume":"8","author":"I Sergin","year":"2017","unstructured":"Sergin, I. et al. Exploiting macrophage autophagy\u2013lysosomal biogenesis as a therapy for atherosclerosis. Nat. Commun. 8, 15750 (2017).","journal-title":"Nat. Commun."},{"key":"1100_CR191","doi-asserted-by":"publisher","first-page":"jcs259402","DOI":"10.1242\/jcs.259402","volume":"135","author":"MB Schott","year":"2022","unstructured":"Schott, M. B., Rozeveld, C. N., Weller, S. G. & McNiven, M. A. Lipophagy at a glance. J. Cell Sci. 135, jcs259402 (2022).","journal-title":"J. Cell Sci."},{"key":"1100_CR192","doi-asserted-by":"publisher","first-page":"103207","DOI":"10.1016\/j.ebiom.2020.103207","volume":"63","author":"H Lu","year":"2021","unstructured":"Lu, H., Sun, J., Hamblin, M. H., Chen, Y. E. & Fan, Y. Transcription factor EB regulates cardiovascular homeostasis. eBioMedicine 63, 103207 (2021).","journal-title":"eBioMedicine"},{"key":"1100_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.433","volume":"7","author":"X Li","year":"2016","unstructured":"Li, X. et al. Hypericin-mediated sonodynamic therapy induces autophagy and decreases lipids in THP-1 macrophage by promoting ROS-dependent nuclear translocation of TFEB. Cell Death Dis. 7, e2527 (2016).","journal-title":"Cell Death Dis."},{"key":"1100_CR194","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1111\/all.15221","volume":"77","author":"E Theofani","year":"2022","unstructured":"Theofani, E. et al. TFEB signaling attenuates NLRP3-driven inflammatory responses in severe asthma. Allergy 77, 2131\u20132146 (2022).","journal-title":"Allergy"},{"key":"1100_CR195","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s00018-023-04981-8","volume":"80","author":"K Wang","year":"2023","unstructured":"Wang, K. et al. TFEB SUMOylation in macrophages accelerates atherosclerosis by promoting the formation of foam cells through inhibiting lysosomal activity. Cell Mol. Life Sci. 80, 358 (2023).","journal-title":"Cell Mol. Life Sci."},{"key":"1100_CR196","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1083\/jcb.129.1.133","volume":"129","author":"HS Kruth","year":"1995","unstructured":"Kruth, H. S., Skarlatos, S. I., Lilly, K., Chang, J. & Ifrim, I. Sequestration of acetylated LDL and cholesterol crystals by human monocyte-derived macrophages. J. Cell Biol. 129, 133\u2013145 (1995).","journal-title":"J. Cell Biol."},{"key":"1100_CR197","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/micmic\/ozad067.592","volume":"29","author":"AD Juhl","year":"2023","unstructured":"Juhl, A. D. et al. Direct observation of uptake and dissolution of cholesterol crystals by macrophages using combined fluorescence and x-ray microscopy. Microsc. Microanal. 29, 1158\u20131159 (2023).","journal-title":"Microsc. Microanal."},{"key":"1100_CR198","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejpb.2022.04.005","volume":"174","author":"J He","year":"2022","unstructured":"He, J. et al. Anchoring \u03b2-CD on simvastatin-loaded rHDL for selective cholesterol crystals dissolution and enhanced anti-inflammatory effects in macrophage\/foam cells. Eur. J. Pharm. Biopharm. 174, 144\u2013154 (2022).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"1100_CR199","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jacbts.2021.08.006","volume":"7","author":"MB Olsen","year":"2022","unstructured":"Olsen, M. B. et al. Targeting the inflammasome in cardiovascular disease. JACC Basic. Transl. Sci. 7, 84\u201398 (2022).","journal-title":"JACC Basic. Transl. Sci."},{"key":"1100_CR200","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/cells10040951","volume":"10","author":"P Libby","year":"2021","unstructured":"Libby, P. Targeting inflammatory pathways in cardiovascular disease: the inflammasome, interleukin-1, interleukin-6 and beyond. Cells 10, 951 (2021).","journal-title":"Cells"},{"key":"1100_CR201","doi-asserted-by":"publisher","first-page":"108053","DOI":"10.1016\/j.pharmthera.2021.108053","volume":"236","author":"S Toldo","year":"2022","unstructured":"Toldo, S. et al. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol. Ther. 236, 108053 (2022).","journal-title":"Pharmacol. Ther."},{"key":"1100_CR202","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.jacbts.2023.03.017","volume":"8","author":"N Potere","year":"2023","unstructured":"Potere, N. et al. Inflammasome signaling, thromboinflammation, and venous thromboembolism. JACC Basic. Transl. Sci. 8, 1245\u20131261 (2023).","journal-title":"JACC Basic. Transl. Sci."},{"key":"1100_CR203","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014044","volume":"9","author":"P Ren","year":"2020","unstructured":"Ren, P. et al. Targeting the NLRP3 inflammasome with inhibitor MCC950 prevents aortic aneurysms and dissections in mice. J. Am. Heart Assoc. 9, e014044 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"1100_CR204","doi-asserted-by":"publisher","first-page":"115861","DOI":"10.1016\/j.bcp.2023.115861","volume":"217","author":"E Ramos-Tovar","year":"2023","unstructured":"Ramos-Tovar, E. & Muriel, P. NLRP3 inflammasome in hepatic diseases: a pharmacological target. Biochem. Pharmacol. 217, 115861 (2023).","journal-title":"Biochem. Pharmacol."},{"key":"1100_CR205","first-page":"101417","volume":"33","author":"G Huang","year":"2023","unstructured":"Huang, G., Zhang, Y., Zhang, Y. & Ma, Y. Chronic kidney disease and NLRP3 inflammasome: pathogenesis, development and targeted therapeutic strategies. Biochem. Biophys. Rep. 33, 101417 (2023).","journal-title":"Biochem. Biophys. Rep."},{"key":"1100_CR206","first-page":"7","volume":"18","author":"Y Hu","year":"2014","unstructured":"Hu, Y. et al. Cholesterol crystals induce inflammatory cytokines expression in a human retinal pigment epithelium cell line by activating the NF-\u03baB pathway. Discov. Med. 18, 7\u201314 (2014).","journal-title":"Discov. Med."},{"key":"1100_CR207","doi-asserted-by":"publisher","first-page":"839041","DOI":"10.3389\/fcell.2022.839041","volume":"10","author":"S Lillo","year":"2022","unstructured":"Lillo, S. & Saleh, M. Inflammasomes in cancer progression and anti-tumor immunity. Front. Cell Dev. Biol. 10, 839041 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"1100_CR208","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3390\/cancers13102297","volume":"13","author":"S Missiroli","year":"2021","unstructured":"Missiroli, S. et al. Targeting the NLRP3 inflammasome as a new therapeutic option for overcoming cancer. Cancers 13, 2297 (2021).","journal-title":"Cancers"},{"key":"1100_CR209","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jacbts.2020.03.016","volume":"5","author":"S Chen","year":"2020","unstructured":"Chen, S. et al. Sex-specific effects of the Nlrp3 inflammasome on atherogenesis in LDL receptor-deficient mice. JACC Basic. Transl. Sci. 5, 582\u2013598 (2020).","journal-title":"JACC Basic. Transl. Sci."},{"key":"1100_CR210","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jacc.2023.05.055","volume":"82","author":"K Nelson","year":"2023","unstructured":"Nelson, K., Fuster, V. & Ridker, P. M. Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week. J. Am. Coll. Cardiol. 82, 648\u2013660 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1100_CR211","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1093\/eurheartj\/ehae208","volume":"45","author":"SM Nidorf","year":"2024","unstructured":"Nidorf, S. M., Ben-Chetrit, E. & Ridker, P. M. Low-dose colchicine for atherosclerosis: long-term safety. Eur. Heart J. 45, 1596\u20131601 (2024).","journal-title":"Eur. Heart J."},{"key":"1100_CR212","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/s12872-021-02393-9","volume":"21","author":"M Akrami","year":"2021","unstructured":"Akrami, M. et al. Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial. BMC Cardiovasc. Disord. 21, 583 (2021).","journal-title":"BMC Cardiovasc. Disord."},{"key":"1100_CR213","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0735-1097(24)02909-7","volume":"83","author":"AFA Al Wssawi","year":"2024","unstructured":"Al Wssawi, A. F. A. et al. Colchicine reduces major adverse cardiovascular events in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials [abstract]. J. Am. Coll. Cardiol. 83, 919 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1100_CR214","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ni.2550","volume":"14","author":"T Misawa","year":"2013","unstructured":"Misawa, T. et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat. Immunol. 14, 454\u2013460 (2013).","journal-title":"Nat. Immunol."},{"key":"1100_CR215","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nri3444","volume":"13","author":"M Papatriantafyllou","year":"2013","unstructured":"Papatriantafyllou, M. Inflammasomes: microtubules pull mitochondria to NLRP3. Nat. Rev. Immunol. 13, 306 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"1100_CR216","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202201469R","volume":"37","author":"N Schwarz","year":"2023","unstructured":"Schwarz, N. et al. Colchicine exerts anti-atherosclerotic and -plaque-stabilizing effects targeting foam cell formation. FASEB J. 37, e22846 (2023).","journal-title":"FASEB J."},{"key":"1100_CR217","doi-asserted-by":"publisher","first-page":"1345521","DOI":"10.3389\/fcvm.2024.1345521","volume":"11","author":"ZU Abideen","year":"2024","unstructured":"Abideen, Z. U., Pathak, D. R., Sabanci, R., Manu, M. & Abela, G. S. The effect of colchicine on cholesterol crystal formation, expansion and morphology: a potential mechanism in atherosclerosis. Front. Cardiovasc. Med. 11, 1345521 (2024).","journal-title":"Front. Cardiovasc. Med."},{"key":"1100_CR218","first-page":"100083","volume":"13","author":"L Fry","year":"2022","unstructured":"Fry, L. et al. Effect of aspirin on cholesterol crystallization: a potential mechanism for plaque stabilization. Am. Heart J. 13, 100083 (2022).","journal-title":"Am. Heart J."},{"key":"1100_CR219","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/CIRCRESAHA.121.319811","volume":"130","author":"TM Powell-Wiley","year":"2022","unstructured":"Powell-Wiley, T. M. et al. Social determinants of cardiovascular disease. Circ. Res. 130, 782\u2013799 (2022).","journal-title":"Circ. Res."},{"key":"1100_CR220","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.3390\/ijerph18084296","volume":"18","author":"N Farmer","year":"2021","unstructured":"Farmer, N. et al. Neighborhood environment associates with trimethylamine-N-oxide (TMAO) as a cardiovascular risk marker. Int. J. Env. Res. Public. Health 18, 4296 (2021).","journal-title":"Int. J. Env. Res. Public. Health"},{"key":"1100_CR221","doi-asserted-by":"publisher","first-page":"106346","DOI":"10.1016\/j.psyneuen.2023.106346","volume":"157","author":"LR Ortiz-Whittingham","year":"2023","unstructured":"Ortiz-Whittingham, L. R. et al. Associations between neighborhood socioeconomic deprivation, IFN\u03b3, and high-density lipoprotein particle size: data from the Washington, D.C. Cardiovascular Health and Nneeds Assessment. Psychoneuroendocrinology 157, 106346 (2023).","journal-title":"Psychoneuroendocrinology"},{"key":"1100_CR222","doi-asserted-by":"publisher","first-page":"11156","DOI":"10.3390\/ijms241311156","volume":"24","author":"P Malkowska","year":"2023","unstructured":"Malkowska, P. & Sawczuk, M. Cytokines as biomarkers for evaluating physical exercise in trained and non-trained individuals: a narrative review. Int. J. Mol. Sci. 24, 11156 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1100_CR223","doi-asserted-by":"publisher","first-page":"5982980","DOI":"10.1155\/2018\/5982980","volume":"2018","author":"AM Albarrati","year":"2018","unstructured":"Albarrati, A. M. et al. Effectiveness of low to moderate physical exercise training on the level of low-density lipoproteins: a systematic review. Biomed. Res. Int. 2018, 5982980 (2018).","journal-title":"Biomed. Res. Int."},{"key":"1100_CR224","first-page":"100036","volume":"2","author":"S Nikara","year":"2020","unstructured":"Nikara, S., Ahmadi, E. & Nia, A. A. Effects of different preparation techniques on the microstructural features of biological materials for scanning electron microscopy. J. Agric. Food Res. 2, 100036 (2020).","journal-title":"J. Agric. Food Res."},{"key":"1100_CR225","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1126\/science.6836303","volume":"220","author":"L-Y Hsu","year":"1983","unstructured":"Hsu, L.-Y. & Nordman, C. Phase transition and crystal structure of the 37 C form of cholesterol. Science 220, 604\u2013606 (1983).","journal-title":"Science"},{"key":"1100_CR226","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0928-4931(96)80002-6","volume":"3","author":"S Kumar","year":"1995","unstructured":"Kumar, S. & Burns, S. Cracking cholesterol from a phase transition at body temperatures. Mater. Sci. Eng. C. 3, 153\u2013158 (1995).","journal-title":"Mater. Sci. Eng. C."},{"key":"1100_CR227","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0005-2736(03)00019-1","volume":"1610","author":"L Addadi","year":"2003","unstructured":"Addadi, L., Geva, M. & Kruth, H. S. Structural information about organized cholesterol domains from specific antibody recognition. Biochim. Biophys. Acta 1610, 208\u2013216 (2003).","journal-title":"Biochim. Biophys. Acta"},{"key":"1100_CR228","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S1074-5521(96)90148-9","volume":"3","author":"D Perl-Treves","year":"1996","unstructured":"Perl-Treves, D., Kessler, N., Izhaky, D. & Addadi, L. Monoclonal antibody recognition of cholesterol monohydrate crystal faces. Chem. Biol. 3, 567\u2013577 (1996).","journal-title":"Chem. Biol."},{"key":"1100_CR229","doi-asserted-by":"publisher","first-page":"131965","DOI":"10.1016\/j.ijcard.2024.131965","volume":"405","author":"C Li","year":"2024","unstructured":"Li, C., Deng, C., Shi, B. & Zhao, R. Thin-cap fibroatheroma in acute coronary syndrome: implication for intravascular imaging assessment. Int. J. Cardiol. 405, 131965 (2024).","journal-title":"Int. J. Cardiol."},{"key":"1100_CR230","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.121.011728","volume":"15","author":"E Fabris","year":"2022","unstructured":"Fabris, E. et al. Thin-cap fibroatheroma rather than any lipid plaques increases the risk of cardiovascular events in diabetic patients: insights from the COMBINE OCT-FFR trial. Circ. Cardiovasc. Interv. 15, e011728 (2022).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"1100_CR231","first-page":"203","volume":"12","author":"T Kubo","year":"2023","unstructured":"Kubo, T. Optical coherence tomography in vulnerable plaque and acute coronary syndrome. Interv. Cardiol. Clin. 12, 203\u2013214 (2023).","journal-title":"Interv. Cardiol. Clin."},{"key":"1100_CR232","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.atherosclerosis.2019.02.009","volume":"283","author":"K Fujiyoshi","year":"2019","unstructured":"Fujiyoshi, K. et al. Incidence, factors, and clinical significance of cholesterol crystals in coronary plaque: an optical coherence tomography study. Atherosclerosis 283, 79\u201384 (2019).","journal-title":"Atherosclerosis"},{"key":"1100_CR233","doi-asserted-by":"publisher","first-page":"131665","DOI":"10.1016\/j.ijcard.2023.131665","volume":"399","author":"G Nelles","year":"2023","unstructured":"Nelles, G. et al. Cholesterol crystals at the culprit lesion in patients with acute coronary syndrome are associated with worse cardiovascular outcomes at two years follow up \u2013 results from the translational OPTICO-ACS study program (R2). Int. J. Cardiol. 399, 131665 (2023).","journal-title":"Int. J. Cardiol."},{"key":"1100_CR234","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.jacc.2014.01.061","volume":"63","author":"J Tian","year":"2014","unstructured":"Tian, J. et al. Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study. J. Am. Coll. Cardiol. 63, 2209\u20132216 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1100_CR235","first-page":"309","volume":"13","author":"K Saiin","year":"2023","unstructured":"Saiin, K. et al. Association of coronary plaque morphology with inflammatory biomarkers and target lesion revascularization in patients with chronic coronary syndrome: an optical coherence tomography study. Am. J. Cardiovasc. Dis. 13, 309\u2013319 (2023).","journal-title":"Am. J. Cardiovasc. Dis."},{"key":"1100_CR236","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jcmg.2023.08.005","volume":"17","author":"D Kinoshita","year":"2024","unstructured":"Kinoshita, D. et al. High-risk plaques on coronary computed tomography angiography: correlation with optical coherence tomography. JACC Cardiovasc. Imaging 17, 382\u2013391 (2024).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"1100_CR237","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.123.015227","volume":"16","author":"LM Seegers","year":"2023","unstructured":"Seegers, L. M. et al. Sex differences in coronary atherosclerotic phenotype and healing pattern on optical coherence tomography imaging. Circ. Cardiovasc. Imaging 16, e015227 (2023).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"1100_CR238","doi-asserted-by":"publisher","first-page":"117118","DOI":"10.1016\/j.atherosclerosis.2023.03.023","volume":"378","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. Pancoronary plaque characteristics and clinical outcomes in acute coronary syndrome patients with cancer history. Atherosclerosis 378, 117118 (2023).","journal-title":"Atherosclerosis"},{"key":"1100_CR239","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/ccd.28574","volume":"96","author":"M Yamaguchi","year":"2020","unstructured":"Yamaguchi, M. et al. Clinical significance of the presence of puff-chandelier ruptures detected by nonobstructive aortic angioscopy. Catheter. Cardiovasc. Interv. 96, 784\u2013792 (2020).","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"1100_CR240","volume":"16","author":"S Komatsu","year":"2024","unstructured":"Komatsu, S. et al. Different characteristics and interleukin-6 ratios of scattering-type aortic plaques. Cureus 16, e52949 (2024).","journal-title":"Cureus"},{"key":"1100_CR241","first-page":"237","volume":"12","author":"K Nishimiya","year":"2023","unstructured":"Nishimiya, K., Poduval, R. K. & Tearney, G. J. OCT emerging technologies: coronary micro-optical coherence tomography. Interv. Cardiol. Clin. 12, 237\u2013244 (2023).","journal-title":"Interv. Cardiol. Clin."},{"key":"1100_CR242","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.atherosclerosis.2016.11.017","volume":"256","author":"Y Baumer","year":"2017","unstructured":"Baumer, Y. et al. CD98 regulates vascular smooth muscle cell proliferation in atherosclerosis. Atherosclerosis 256, 105\u2013114 (2017).","journal-title":"Atherosclerosis"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-024-01100-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-024-01100-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-024-01100-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T12:03:24Z","timestamp":1744805004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-024-01100-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":242,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1100"],"URL":"https:\/\/doi.org\/10.1038\/s41569-024-01100-3","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"23 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}